Management of Rosacea-Prone Skin: Evaluation of a Skincare Product Containing Ambophenol, Neurosensine, and La Roche-PosayThermal Spring Water as Monotherapy or Adjunctive Therapy

August 2013 | Volume 12 | Issue 8 | Original Article | 920 | Copyright © August 2013

Sophie Seité PhD,a Florence Benech PharmD,b Sandrine Berdah PhD,b Muriel Bayer PharmD,b Sophie Veyrat PharmD,b Evelyne Segot PharmD PhD,b Marcela Sakalikova Mgr,c Lucia Gibejova Mgr,c Hana Zelenkova MD PhDc

aLa Roche-Posay Pharmaceutical Laboratories, Asnières, France
bL’Oréal Research and Innovation, Chevilly Larue, France
cDOST Svidnik, Private Clinic of Dermatovenerology, Svidnik, Slovakia

table 2
In addition, the tolerance and the satisfaction with the test formula were good to excellent in 85% and 74% of cases respectively and in 77% of cases, patients noticed a positive impact on their skin quality.
table 3

Evaluation of Tolerance as Adjunctive Therapy

Test formula has been also used by patients with stage 1 or stage 2 rosacea as adjunctive therapy with Metronidazole (n=181); Azelaic acid (n=23); Erythromycin (n=14); Doxycycline (n=31); Minocyclin (n=7); Isotretinoin (n=11); Ichtyol (n=107); Vascular laser (n=16); IPL (n=43) with a “good to excellent” tolerance and satisfaction in more than 80% of cases (data not shown).

Evaluation of the Efficacy Post-Prescription Treatment

Lastly, test formula was used in association with a leading rosacea prescription medicine (Metronidazole) for 8 weeks and for an additional 8 weeks following treatment withdrawal. After 16 weeks, the percentage of patients with global improvement in the signs of rosacea stayed significantly higher in the group treated with the test formula compared to the one treated with the vehicle (Figure 4). The formula containing Ambophenol, Neurosensine, and La Roche-Posay thermal spring water helped prolong the efficacy of the Metronidazole treatment.


Topical agents provide the mainstay of treatment for many patients with rosacea. The three primary drugs approved for the topical treatment of rosacea are azelaic acid, metronidazole and sodium sulfacetamide-sulphur.1 Their efficacy has been validated by multiple studies. A number of other topical therapies are used in rosacea but are not approved for the indication.1 This also includes adapted skincare and cosmetics. We have evaluated the test formula in association to various topical therapies with good tolerance and satisfaction.
We have also shown that the test formula in erythro-couperosis patients can significantly reduce redness and telangiectasia intensity after a 1 month treatment and that this effect was prolonged even 1 week after the end of treatment.